On August 12, GALAXY ENT rose 3.21% in regular trading, trading at HK$34.14/share, with turnover of HK$199 million. The move came immediately after the company released its interim results for the first half of the year.

GALAXY ENT reported net revenue of HK$24.2 billion for the six months ended June 30, representing a 4% year-over-year increase. Net profit attributable to shareholders reached HK$5.29 billion, up 0.51% YoY, with basic EPS of HK$1.202. Adjusted EBITDA was HK$7 billion, up 1% YoY. Notably, after stripping out the approximately HK$23 million negative impact from below-normal win rates, normalized adjusted EBITDA grew 14% YoY. The company also declared an interim dividend of HK$0.9 per share, payable on September 15.

Multiple investment banks have maintained bullish stances on the stock. Citi previously assigned a Buy rating with a HK$44 target price, citing GALAXY ENT's EBITDA market share gains and long-term expansion plans including Phase 4 development. The stock remains a sector top pick at several brokerages.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)